New Strategies for Improving Heart Failure Management: A Primary Care Perspective

Southern Medical Journal

Volumn 94, Issue 2, 2001, Pages 166-174

  Basile, Jan ^a,b  

^a RALPH H JOHNSON VA MEDICAL CENTER   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR AGENT;

ARTICLE; CONGESTIVE HEART FAILURE; COST OF ILLNESS; ECONOMICS; GENERAL PRACTICE; HUMAN; PRACTICE GUIDELINE; UNITED STATES;

CARDIOVASCULAR AGENTS; COST OF ILLNESS; FAMILY PRACTICE; HEART FAILURE, CONGESTIVE; HUMANS; PRACTICE GUIDELINES; UNITED STATES;

EID: 0035260674     PISSN: 00384348     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007611-200194020-00001     Document Type: Article

References (30)

1. Massie BM, Shah NB: Evolving trends in the epidemiologic factors of heart failure: rationale for preventive strategies and comprehensive disease management. Am Heart J 1997; 133:703-712
2. American Heart Association: 1999 Heart and Stroke Statistical Update. Dallas, Tex, American Heart Association, 1998
3. Kannel WB, Belanger AJ: Epidemiology of heart failure. Am Heart J 1991; 121:951-957
4. Chin MH, Goldman L: Correlates of early hospital readmission or death in patients with congestive heart failure. Am J Cardiol 1997; 79:1640-1644
5. Vinson JM, Rich MW, Sperry JG, et al: Early readmission of elderly patients with congestive heart failure. J Am Geriatr Soc 1990; 38:1290-1295
6. O'Connell JB, Bristow MR: Economic impact of heart failure in the United States: time for a different approach. J Heart Lung Transplant 1994; 13(suppl):S107-S112
7. Kannel WB, Ho K, Thom T: Changing epidemiological features of cardiac failure. Br Heart J 1994; 72(suppl):S3-S9
8. Packer M, Cohn JN, eds: Consensus recommendations for the management of chronic heart failure. Am J Cardiol 1999; 83(suppl 2A):1A-38A
9. Cohn JN: The management of chronic heart failure. N Engl J Med 1996; 335:490-498
10. Packer M: The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol 1992; 20:248-254
11. Packer M: β-Adrenergic blockade in chronic heart failure: principles, progress, and practice. Prog Cardiovasc Dis 1998; 41(suppl):39-52
12. The CONSENSUS Trial Study Group: Effects of enalapril on mortality in severe congestive heart failure, results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316:1429-1435
13. The SOLVD Investigators: Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325:293-302
14. Garg R, Yusuf S, for the Collaborative Group on ACE Inhibitor Trials: Overview of randomized trials of angiotensin-convening enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 1995; 273:1450-1456
15. Rajfer SI: Perspective of the pharmaceutical industry on the development of new drugs for heart failure. J Am Coll Cardiol 1993; 22(suppl):198-200
16. Packer M: Do angiotensin-converting enzyme inhibitors prolong life in patients with heart failure treated in clinical practice? J Am Coll Cardiol 1996; 28:1323-1327
17. The Captopril-Digoxin Multicenter Research Group: Comparative effects of therapy with captopril and digoxin in patients with mild to moderate heart failure. JAMA 1998; 259:539-544
18. Cohn JN, Johnson G, Ziesche S, et al: A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991; 325:303-310
19. Packer M, Poole-Wilson P, Armstrong P, et al: Comparative effects of low-dose versus high-dose lisinopril on survival and major events in chronic heart failure: the Assessment and Treatment With Lisinopril and Survival Study (ATLAS). Eur Heart J 1998: 19(suppl):142
20. CIBIS-II Investigators and Committees: The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999; 353:9-13
21. MERIT-HF Study Group: Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353:2001-2007
22. Colucci WS, Packer M, Bristow MR, et al, for the US Carvedilol Heart Failure Study: Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. Circulation 1996; 94:2800-2806
23. Packer M, Colucci WS, Sackner-Bernstein JD, et al, for the PRECISE Study Group: Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure, the PRECISE Trial. Circulation 1996; 94:2793-2799
24. Bristow MR, Gilbert EM, Abraham WT, et al, for the MOCHA Investigators: Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 1996; 94:2807-2816
25. Cohn JN, Fowler MB, Bristow MR, et al, for the US Carvedilol Heart Failure Study Group: Safety and efficacy of carvedilol in severe heart failure. J Card Fail 1997; 3:173-179
26. Packer M, Bristow MR, Cohn JN, et al, for the US Carvedilol Heart Failure Study Group: The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996; 334:1349-1355
27. The Digitalis Investigation Group: The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997; 336:525-533
28. Pitt B, Zannad F, Reme W, et al: The effects of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341:709-717
29. Pitt B, Segal R, Martinez FA, et al, on behalf of the ELITE Study Investigators: Randomized trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study [ELITE]). Lancet 1996; 2:47-54
30. McKelvie R, Yusuf S, Perica KD, et al: Comparison of candesartan, enalapril, and their combination in congestive heart failure: Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) pilot study. (Abstract) Eur Heart J 1998; 19(suppl):133